Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 6Leukemia, Lymphocytic, Chronic, B-Cell 4Prostatic Neoplasms 3Lymphoma, Follicular 3Small Cell Lung Carcinoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Locally Advanced Esophageal or GE Junction Cancer 1Laryngeal Neoplasms 1Hormone Refractory Prostate Cancer 1Gliosarcoma 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer 1Disease 1Burkitt Lymphoma 1Brain Neoplasms 1Adrenocortical Carcinoma 1

Interventions

gossypol acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Esophageal or GE Junction Cancer × gossypol acetic acid × Clear all
NCT00561197 2013-01-04

An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

Ascenta Therapeutics

Phase 1/2 Terminated
13 enrolled
Gastrointestinal

Locally Advanced Esophageal or GE Junction Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡